JP2019510741A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510741A5
JP2019510741A5 JP2018540718A JP2018540718A JP2019510741A5 JP 2019510741 A5 JP2019510741 A5 JP 2019510741A5 JP 2018540718 A JP2018540718 A JP 2018540718A JP 2018540718 A JP2018540718 A JP 2018540718A JP 2019510741 A5 JP2019510741 A5 JP 2019510741A5
Authority
JP
Japan
Prior art keywords
buffer
cytotoxic agent
ala
val
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016344 external-priority patent/WO2017136623A1/en
Publication of JP2019510741A publication Critical patent/JP2019510741A/ja
Publication of JP2019510741A5 publication Critical patent/JP2019510741A5/ja
Pending legal-status Critical Current

Links

JP2018540718A 2016-02-05 2017-02-03 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス Pending JP2019510741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662292018P 2016-02-05 2016-02-05
US62/292,018 2016-02-05
PCT/US2017/016344 WO2017136623A1 (en) 2016-02-05 2017-02-03 Efficient process for preparing cell-binding agent-cytotoxic agent conjugates

Publications (2)

Publication Number Publication Date
JP2019510741A JP2019510741A (ja) 2019-04-18
JP2019510741A5 true JP2019510741A5 (cg-RX-API-DMAC10.html) 2020-03-12

Family

ID=58159509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540718A Pending JP2019510741A (ja) 2016-02-05 2017-02-03 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス

Country Status (12)

Country Link
US (1) US20210299265A1 (cg-RX-API-DMAC10.html)
EP (1) EP3411077A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019510741A (cg-RX-API-DMAC10.html)
KR (1) KR20180105233A (cg-RX-API-DMAC10.html)
CN (1) CN108601848A (cg-RX-API-DMAC10.html)
AU (1) AU2017213858A1 (cg-RX-API-DMAC10.html)
CA (1) CA3013125A1 (cg-RX-API-DMAC10.html)
MA (1) MA47022A (cg-RX-API-DMAC10.html)
RU (1) RU2018130108A (cg-RX-API-DMAC10.html)
SG (1) SG11201806478PA (cg-RX-API-DMAC10.html)
TW (1) TW201731532A (cg-RX-API-DMAC10.html)
WO (1) WO2017136623A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966932A1 (en) * 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
DK3529269T3 (da) 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
WO2018115485A1 (en) 2016-12-22 2018-06-28 Pierfrancesco Tassone A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
MX2020013466A (es) * 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
KR102284800B1 (ko) * 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IL111748A0 (en) 1993-12-03 1995-01-24 Zeneca Ltd Proteins
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
AU2004224925C1 (en) 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
KR101281501B1 (ko) 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US9090629B2 (en) 2010-11-03 2015-07-28 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012095347A1 (en) 2011-01-10 2012-07-19 Technische Universität München Triazacyclononane-based phosphinate ligand and its use for molecular imaging
SI2675480T1 (sl) * 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
EA033468B1 (ru) * 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
WO2012177837A2 (en) * 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates

Similar Documents

Publication Publication Date Title
RU2018130108A (ru) Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
Kong et al. Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA
Zhao et al. Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates
Park et al. Enhanced BBB permeability of osmotically active poly (mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease
Doronina et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
ES2895369T3 (es) Agonistas del receptor tipo toll 7 (TLR7) que tienen un resto tricíclico, conjugados de estos y métodos y usos de estos
DeVay et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates
AU2015273098B2 (en) Auristatin derivatives and conjugates thereof
Bauhuber et al. Delivery of nucleic acids via disulfide‐based carrier systems
Dorywalska et al. Effect of attachment site on stability of cleavable antibody drug conjugates
JP3222461B2 (ja) 新規タンパク質―ポリカチオン結合体
JP2024542073A (ja) 抗体薬物結合体のための特異的共役
Salomon et al. Optimizing lysosomal activation of antibody–drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers
US20250326866A1 (en) Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
Dhande et al. N-acetylgalactosamine block-co-polycations form stable polyplexes with plasmids and promote liver-targeted delivery
JP2018058902A5 (cg-RX-API-DMAC10.html)
WO2021068890A1 (zh) 溶酶体靶向的抗体-药物偶联物及其应用
US20220096652A1 (en) Acetal-based cleavable linkers
He et al. Combinatorial optimization of sequence-defined oligo (ethanamino) amides for folate receptor-targeted pDNA and siRNA delivery
JP2004532217A5 (cg-RX-API-DMAC10.html)
JP7057391B2 (ja) タンパク薬物複合体で使用するためのリンカーに関連する材料および方法
CA2444535A1 (en) Formoterol/steroid bronchodilating compositions and methods of use thereof
JP2007527421A5 (cg-RX-API-DMAC10.html)
KR20160136289A (ko) 단백질의 선택적 환원
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты